GYG Gyg Plc

RNS Number:3719V
Gyrus Group PLC
7 December 2000


GYRUS GROUP PLC
("Gyrus" or the "Company")

GYRUS LAPAROSCOPIC PLASMAKINETIC SYSTEM NOW OPERATIONAL IN THE U.S. 


*  Following FDA 510(k) approval, surgeons in the United States have
successfully performed the first laparoscopic cases using Gyrus' PlasmaKinetic
(PK) system.

*  The power, speed and control of the PK generator technology has been
tailored to maximise the performance of Everest's laparoscopic instrument
range beyond that currently available to surgeons.

*  This introduction provides the basis from which a comprehensive system
based approach to tissue management during surgical procedures will be
developed.

*  The system is being introduced into a number of key centres in both the US
and Europe prior to full release towards end of Q1 2001.

* Laparoscopy (keyhole surgery performed in the abdomen) now represents the
largest and fastest growing sector of Gyrus' business.

Commenting on this announcement Dr Mark Goble, Gyrus Group CEO, said:

"This has been a very fast track development, from concept to market
introduction in a little over seven months.  It clearly demonstrates our
responsiveness to market needs and forms an important step towards our goal of
building direct sales on a platform of total tissue management during surgical
procedures".  


GYRUS LAPAROSCOPIC PLASMAKINETIC SYSTEM NOW OPERATIONAL IN THE U.S.


Following FDA 510(k) approval, surgeons in the United States have successfully
performed the first procedures using the Gyrus laparoscopic PlasmaKinetic (PK)
system.  Laparoscopy, keyhole surgery performed in the abdomen, accounts for
approximately 35% of the $5 billion minimal access surgery market and is the
fastest growing sector of Gyrus' business following the acquisition of Everest
in April.

To date, the positioning of Everest's instruments in the market has been based
on their multi-functionality reducing operating time and costs.  Whilst this
strategy has proved very successful, it has been limited by its reliance on
the variable performance of a range of different electrosurgical generators in
the market. The power, speed and control of the PK generator technology has
been tailored to maximise the performance of Everest's laparoscopic instrument
range beyond that currently available to surgeons.

The PK system is now being introduced into a number of  key centres in both
the US and Europe prior to full release towards the end of Q1 2001.  The
results from these centres will be used to support scientific presentations
planned for 2001.

As market experience with the system grows Gyrus anticipates that the scope
for new procedure opportunities will expand.  The launch of this laparoscopic
PK system is the first in a series of development projects targeted at
integrating Gyrus' technology with that of Everest's to produce a
comprehensive system-based approach to tissue management during surgical
procedures.  

Integrating the Gyrus Endourology system with the laparoscopic PK system to
address the fast growing laparoscopic urology market, is the next target. 
This will provide the urological surgeon with a versatile endoscopic system
for both abdominal and urethral surgery to treat kidneys, bladder and
prostate. 

Commenting on this announcement Dr Mark Goble, Gyrus Group CEO, said:

"This has been a very fast track development, from concept to market
introduction in a little over seven months.  It clearly demonstrates our
responsiveness to market needs and forms an important step towards our goal of
building direct sales on a platform of total tissue management during surgical
procedures".  

Gyrus Group PLC has its UK Administrative Headquarters in Bourne End and the
Manufacturing Division in Cardiff.  Further information on the company is
available on request from Jean Garon PR by calling (01628) 483040 or Fax:
(01628) 486796.    You can also visit the Gyrus web site at: www.gyrus.co.uk

Information in this press release may include forward looking statements which
embrace risk and uncertainties.  However all information included in this text
is based on information available to our client at the time of issue.  These
statements are not guarantees of future performance and actual results could
differ materially from current expectations.

ENQUIRIES


Gyrus Group PLC                                   
Dr Mark Goble, Group CEO                            
Analyst/Broker/Shareholder Enquiries              
Tel: (01628) 535800
Fax: (01628) 535801
E-Mail: mark.goble@gyrusplc.com


Jean Garon PR                                   
Jean Garon                                          
Press Enquiries              
Tel: (01628) 483040
Fax: (01628) 486796
E-Mail: jean@garonpr.demon.co.uk

Gyg (LSE:GYG)
Historical Stock Chart
Von Jun 2024 bis Jul 2024

Gyg (LSE:GYG)
Historical Stock Chart
Von Jul 2023 bis Jul 2024